TaiGen Biopharmaceuticals Holdings Limited (TPEX: 4157)
Taiwan
· Delayed Price · Currency is TWD 14.50
+0.55 (3.94%)
Sep 10, 2024, 1:30 PM CST
TaiGen Biopharmaceuticals Holdings Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 149.45 | 123.13 | 36.23 | 1,295 | 23.42 | 20.31 | Upgrade
|
| Revenue Growth (YoY) | 15.77% | 239.87% | -97.20% | 5426.95% | 15.30% | -31.41% | Upgrade
|
| Cost of Revenue | 13.43 | 11.45 | 3.74 | 12.72 | 4.04 | 7.6 | Upgrade
|
| Gross Profit | 136.03 | 111.69 | 32.49 | 1,282 | 19.39 | 12.71 | Upgrade
|
| Selling, General & Admin | 105.73 | 98.9 | 72.64 | 99.06 | 77.27 | 66.29 | Upgrade
|
| Research & Development | 189.07 | 187.48 | 237.52 | 283.28 | 249.44 | 223.56 | Upgrade
|
| Operating Expenses | 294.8 | 286.39 | 310.16 | 382.34 | 326.71 | 289.84 | Upgrade
|
| Operating Income | -158.77 | -174.7 | -277.67 | 899.46 | -307.32 | -277.13 | Upgrade
|
| Interest Expense | -1.6 | -1.14 | -0.85 | -0.24 | -0.6 | -1.03 | Upgrade
|
| Interest & Investment Income | 23.2 | 20.38 | 8.72 | 4.23 | 3.5 | 8.62 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -23.24 | -113.04 | -133.96 | Upgrade
|
| Currency Exchange Gain (Loss) | 52.7 | -15.68 | 51.79 | -4.24 | 13.08 | -38.45 | Upgrade
|
| Other Non Operating Income (Expenses) | 149.83 | 149.4 | 0.01 | 0.04 | - | -0.11 | Upgrade
|
| EBT Excluding Unusual Items | 65.36 | -21.73 | -218 | 876 | -404.38 | -442.07 | Upgrade
|
| Gain (Loss) on Sale of Investments | 173.86 | 165.22 | 0.3 | 0.08 | 0.43 | 151.89 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.08 | 0.01 | - | Upgrade
|
| Asset Writedown | - | - | -12.06 | - | -2.92 | - | Upgrade
|
| Pretax Income | 239.23 | 143.49 | -229.77 | 875.99 | -406.87 | -290.18 | Upgrade
|
| Income Tax Expense | 4.07 | 6.76 | 7.4 | 100.37 | -2.06 | 5.51 | Upgrade
|
| Net Income | 235.16 | 136.73 | -237.16 | 775.62 | -404.82 | -295.69 | Upgrade
|
| Net Income to Common | 235.16 | 136.73 | -237.16 | 775.62 | -404.82 | -295.69 | Upgrade
|
| Shares Outstanding (Basic) | 743 | 717 | 717 | 717 | 717 | 717 | Upgrade
|
| Shares Outstanding (Diluted) | 743 | 717 | 717 | 717 | 717 | 717 | Upgrade
|
| Shares Change (YoY) | 6.98% | 0.06% | -0.07% | 0.07% | 0.01% | 0.01% | Upgrade
|
| EPS (Basic) | 0.32 | 0.19 | -0.33 | 1.08 | -0.56 | -0.41 | Upgrade
|
| EPS (Diluted) | 0.32 | 0.19 | -0.33 | 1.08 | -0.56 | -0.41 | Upgrade
|
| Free Cash Flow | -197.97 | 3.57 | -24.66 | 618.83 | -247.56 | -346.39 | Upgrade
|
| Free Cash Flow Per Share | -0.27 | 0.00 | -0.03 | 0.86 | -0.35 | -0.48 | Upgrade
|
| Gross Margin | 91.02% | 90.70% | 89.69% | 99.02% | 82.77% | 62.57% | Upgrade
|
| Operating Margin | -106.23% | -141.88% | -766.41% | 69.48% | -1312.10% | -1364.25% | Upgrade
|
| Profit Margin | 157.35% | 111.04% | -654.61% | 59.92% | -1728.37% | -1455.57% | Upgrade
|
| Free Cash Flow Margin | -132.46% | 2.90% | -68.06% | 47.80% | -1056.95% | -1705.17% | Upgrade
|
| EBITDA | -150.54 | -164.59 | -267.53 | 909.9 | -295.49 | -264.95 | Upgrade
|
| EBITDA Margin | -100.72% | -133.67% | - | 70.29% | - | - | Upgrade
|
| D&A For EBITDA | 8.23 | 10.11 | 10.14 | 10.44 | 11.83 | 12.19 | Upgrade
|
| EBIT | -158.77 | -174.7 | -277.67 | 899.46 | -307.32 | -277.13 | Upgrade
|
| EBIT Margin | -106.23% | -141.88% | - | 69.48% | - | - | Upgrade
|
| Effective Tax Rate | 1.70% | 4.71% | - | 11.46% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.